BioLine Rx (FRA:YP2) Common Stock: €63.52 Mil (As of Mar. 2026)


FRA:YP2 BioLine Rx Ltd FRA:YP2
21 GF Score
Price €2.52
! 5 Warning Signs
View Full Analysis

What is BioLine Rx Common Stock?

BioLine Rx FRA:YP2 -0.79% 21 Common Stock is €63.52 Mil as of Mar. 2026. GuruFocus rates FRA:YP2 with a GF Score™ of 21/100. The stock has 5 warning signs investors should review.

BioLine Rx's quarterly common stock increased from Sep. 2025 (€62.56 Mil) to Dec. 2025 (€62.71 Mil) and increased from Dec. 2025 (€62.71 Mil) to Mar. 2026 (€63.52 Mil).

BioLine Rx's annual common stock increased from Dec. 2023 (€28.75 Mil) to Dec. 2024 (€36.38 Mil) and increased from Dec. 2024 (€36.38 Mil) to Dec. 2025 (€62.71 Mil).

BioLine Rx Common Stock Historical Data

* Premium members only.

The historical data trend for BioLine Rx's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioLine Rx Common Stock Chart

BioLine Rx Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.64 25.58 28.75 36.38 62.71

BioLine Rx Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 57.88 62.27 62.56 62.71 63.52
FRA:YP2
21GF Score
BioLine Rx Ltd FRA:YP2
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioLine Rx Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of €63.52 Mil mean?
BioLine Rx (FRA:YP2) has a Common Stock of €63.52 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on BioLine Rx and its competitors.
Is BioLine Rx's Common Stock too high?
BioLine Rx's current Common Stock is €63.52 Mil. Overall, BioLine Rx has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does BioLine Rx's Common Stock compare to VRTX and REGN?
BioLine Rx's Common Stock of €63.52 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on BioLine Rx and its competitors. BioLine Rx's current Common Stock is €63.52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLine Rx stock overvalued right now?
BioLine Rx (FRA:YP2) has a current Common Stock of €63.52 Mil. The current Common Stock is €63.52 Mil. BioLine Rx's overall GF Score™ is 21/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For BioLine Rx (FRA:YP2), the current Common Stock is €63.52 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioLine Rx Business Description

Other Exchanges BLRX:USABLRX:Israel
Address 2 HaMa’ayan Street, Modi’in, ISR, 7177871
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
21GF Score

Get the complete analysis for FRA:YP2

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.52
Price